Alternate-Day Buprenorphine Administration. Phase VII - 8 - Full Text View

Alternate-Day Buprenorphine Administration. Phase VII - 8

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Vermont
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000226

Purpose

The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase II

ChemIDplus related topics:

Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Alternate-Day Buprenorphine Administration. Phase VII

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Opioid withdrawal
Opioid agonist effects
Pupil diameter

Estimated Enrollment:	0
Study Start Date:	November 1994

Eligibility

Ages Eligible for Study:	21 Years to 48 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000226

Locations


United States, Vermont
	Treatment Research Center
	Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Vermont

Investigators


Principal Investigator:	Warren Bickel, Ph.D.	University of Vermont

More Information

Study ID Numbers:	NIDA-06969-8, R01-06969-8
First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000226
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine

Mental Disorders

Substance-Related Disorders

Disorders of Environmental Origin

Opioid-Related Disorders

Additional relevant MeSH terms:

Sensory System Agents

Therapeutic Uses

Narcotic Antagonists

Physiological Effects of Drugs

Central Nervous System Depressants

Narcotics

Peripheral Nervous System Agents

Analgesics

Central Nervous System Agents

Pharmacologic Actions

Analgesics, Opioid

ClinicalTrials.gov processed this record on October 10, 2008